Redx Pharma Plc (LON:REDX) has emerged from administration with a refocused R&D pipeline and in a very clean financial state with £13.6m net cash in the bank. The group’s strategy
‘In God we trust’ is the official motto of the United States of America, second only perhaps to real estate (in a politically correct World). This latter dictum derives from
In the November edition of the Hardman Monthly Newsletter, Nigel Hawkins assesses the achievements of AIM – and how it has thrived, despite a challenging financial environment, in recent years.
Murgitroyd Group plc (LON:MUR) announced results on 12th September, with a welcome return to PBT growth in H2 (+6.9% vs prior year, EPS -8.4% due to tax charge which contained
Hardman and Co’s Keith Hiscock discusses his recent article ‘Liquidity – little understood, even before MiFID II’ in this exclusive interview with DirectorsTalk
Chamberlin Plc (LON:CMH) remains on track strategically, developing its product offering to the automobile turbocharger industry through expansion of its principal operational facilities. Revenue growth is meeting expectations but one-off
Alliance Pharma Plc (LON:APH) buy-and-build strategy is to evolve into a profitable, cash generative, specialty pharma business is bearing fruit. Acquisition of the dermatology and wound care products from Sinclair
Avacta Group Plc (LON:AVCT) is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology
Tissue Regenix Group Plc (LON:TRX) has a broad portfolio of regenerative medicine products developed from decellularised human and porcine soft tissues for the wound care, orthopaedics, and cardiac markets. Since
Allergy Therapeutics Plc (LON:AGY) is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro continues to gain market share despite being available in the EU only
© 2023 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
